Yondelis trabectedin: Additional Phase II data

An NDA for Yondelis is under Priority Review in the U.S. to treat advanced STS in patients who have received prior chemotherapy, including an anthracycline. The drug is marketed in

Read the full 300 word article

How to gain access

Continue reading with a
two-week free trial.